Anish Thomas

National Institutes of Health

Full Professor(heuristic)

Lung Cancer Research Studies · Oncology

h-index55

i10-index133

Publications572

Citations13,899

Grants

10 total · 0 active

NIH #1ZICBC012174-02

Development Therapeutics Branch-Translational Medicine and Therapeutics Group

Amount: $1.0M
Period: — → —
PIs: 1
Est. capacity / PI: ~16 students

Awarded at DIVISION OF BASIC SCIENCES - NCI

NIH #1ZIABC011793-08

Exploiting DNA Replicative Stress for Novel Small Cell Lung Cancer Therapies

Amount: $4.1M
Period: — → —
PIs: 1
Est. capacity / PI: ~67 students

Awarded at DIVISION OF BASIC SCIENCES - NCI

NIH #1ZIABC011793-07

Exploiting DNA Replicative Stress for Novel Small Cell Lung Cancer Therapies

Amount: $3.3M
Period: — → —
PIs: 1
Est. capacity / PI: ~54 students

Awarded at DIVISION OF BASIC SCIENCES - NCI

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

All Grants

10 total · 0 active

NIH #1ZICBC012174-02

Development Therapeutics Branch-Translational Medicine and Therapeutics Group

Amount: $1.0M
Period: — → —
PIs: 1
Est. capacity / PI: ~16 students

Awarded at DIVISION OF BASIC SCIENCES - NCI

NIH #1ZIABC011793-08

Exploiting DNA Replicative Stress for Novel Small Cell Lung Cancer Therapies

Amount: $4.1M
Period: — → —
PIs: 1
Est. capacity / PI: ~67 students

Awarded at DIVISION OF BASIC SCIENCES - NCI

NIH #1ZIABC011793-07

Exploiting DNA Replicative Stress for Novel Small Cell Lung Cancer Therapies

Amount: $3.3M
Period: — → —
PIs: 1
Est. capacity / PI: ~54 students

Awarded at DIVISION OF BASIC SCIENCES - NCI

NIH #1ZICBC012174-01

Development Therapeutics Branch-Translational Medicine and Therapeutics Group

Amount: $813K
Period: — → —
PIs: 1
Est. capacity / PI: ~13 students

Awarded at DIVISION OF BASIC SCIENCES - NCI

NIH #1ZIABC011793-06

Exploiting DNA Replicative Stress for Novel Small Cell Lung Cancer Therapies

Amount: $2.2M
Period: — → —
PIs: 1
Est. capacity / PI: ~36 students

Awarded at DIVISION OF BASIC SCIENCES - NCI

NIH #1ZIABC011793-05

Exploiting DNA Replicative Stress for Novel Small Cell Lung Cancer Therapies

Amount: $1.5M
Period: — → —
PIs: 1
Est. capacity / PI: ~24 students

Awarded at DIVISION OF BASIC SCIENCES - NCI

NIH #1ZIABC011793-04

Exploiting DNA Replicative Stress for Novel Small Cell Lung Cancer Therapies

Amount: $1.5M
Period: — → —
PIs: 1
Est. capacity / PI: ~25 students

Awarded at DIVISION OF BASIC SCIENCES - NCI

NIH #1ZIABC011793-03

Exploiting DNA Replicative Stress for Novel Small Cell Lung Cancer Therapies

Amount: $1.4M
Period: — → —
PIs: 1
Est. capacity / PI: ~23 students

Awarded at DIVISION OF BASIC SCIENCES - NCI

NIH #1ZIABC011793-02

Exploiting DNA Replicative Stress for Novel Small Cell Lung Cancer Therapies

Amount: $1.4M
Period: — → —
PIs: 1
Est. capacity / PI: ~23 students

Awarded at DIVISION OF BASIC SCIENCES - NCI

NIH #1ZIABC011793-01

Exploiting DNA Replicative Stress for Novel Small Cell Lung Cancer Therapies

Amount: $972K
Period: — → —
PIs: 1
Est. capacity / PI: ~16 students

Awarded at DIVISION OF BASIC SCIENCES - NCI

Lab Funding Health

Find elsewhere

Institution / lab homepage Search on ResearchGate

In-Field Influence

0.0046

PageRank within Oncology co-authorship network

Explore collaboration map

Admission Signals

New paper: Treatment and Outcomes for Acute Ischemic Stroke in Cardiomyopathy Patients With Heart Failure: A Retrospective Cross-Sectional Study (Cardiology in Review)2026-05-07

Data Freshness

Publications as of 2026-07-01
Grants as of 2026-06-30

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

ORCID: 0000-0003-3293-3115

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 86

Treatment and Outcomes for Acute Ischemic Stroke in Cardiomyopathy Patients With Heart Failure: A Retrospective Cross-Sectional Study
Cardiology in Review · 2026-05-07 · 1 citations
Blockade of Tumor-Intrinsic TGFβ Signaling Drives Hyperprogression in Small Cell Lung Cancer
Cancer Discovery · 2026-04-22
Incidence, Mortality, and Federal Research Funding by Cancer Type in the US
JAMA Network Open · 2026-04-20
Supplementary Figure S3 from SMARCA4 Loss Promotes Late-Stage Tumor Progression in Nonneuroendocrine Small Cell Lung Cancer
2026-03-03
Supplementary Figure S8 from SMARCA4 Loss Promotes Late-Stage Tumor Progression in Nonneuroendocrine Small Cell Lung Cancer
2026-03-03
Supplementary Figure S5 from SMARCA4 Loss Promotes Late-Stage Tumor Progression in Nonneuroendocrine Small Cell Lung Cancer
2026-03-03
Supplementary Figure S2 from SMARCA4 Loss Promotes Late-Stage Tumor Progression in Nonneuroendocrine Small Cell Lung Cancer
2026-03-03
Data from SMARCA4 Loss Promotes Late-Stage Tumor Progression in Nonneuroendocrine Small Cell Lung Cancer
2026-03-03
Supplementary Figure S4 from SMARCA4 Loss Promotes Late-Stage Tumor Progression in Nonneuroendocrine Small Cell Lung Cancer
2026-03-03
Supplementary Figure S1 from SMARCA4 Loss Promotes Late-Stage Tumor Progression in Nonneuroendocrine Small Cell Lung Cancer
2026-03-03
Supplementary Figure S7 from SMARCA4 Loss Promotes Late-Stage Tumor Progression in Nonneuroendocrine Small Cell Lung Cancer
2026-03-03
Supplementary Figure S6 from SMARCA4 Loss Promotes Late-Stage Tumor Progression in Nonneuroendocrine Small Cell Lung Cancer
2026-03-03
Supplementary Table S1 from SMARCA4 Loss Promotes Late-Stage Tumor Progression in Nonneuroendocrine Small Cell Lung Cancer
2026-03-03
A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250)
ESMO Open · 2025-12-19
Table S1 from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
2025-12-11
Table S2 from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
2025-12-11
Figure S5 from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
2025-12-11
Table S4 from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
2025-12-11
Figure S2 from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
2025-12-11
Table S5 from Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
2025-12-11

Open author page on OpenAlex →